AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05292911
Drug: ALT-801
RxNorm normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously (SC)
Trial: NCT04726280
Drug: Ropivacaine 0.75% Injectable Solution
RxNorm normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml extrafascial interscalene brachial plexus block
Trial: NCT04726280
Drug: Ropivacaine 0.75% Injectable Solution
RxNorm normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml extrafascial interscalene brachial plexus block
Trial: NCT05191888
Drug: Vonoprazan and Amoxicillin
RxNorm normalized name: vonoprazan and amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day vonoprazan high-dose two-in-one therapy
Trial: NCT04873934
Drug: Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
Trial: NCT05778084
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
Trial: NCT05220319
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
Trial: NCT06405737
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject assigned to receive intranasal administration of oxytocin (24 IU).
Trial: NCT05001152
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Taste assessment
Trial: NCT04947345
Drug: Remimazolam Besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam Besylate are used as sedatives for subjects in this arm.
Trial: NCT04947345
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol are used as sedatives for subjects in this arm.
Trial: NCT05711381
Drug: HM15912
RxNorm normalized name: HM15912
DrugBank: HM15912 (DB18266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: HM15912 Active 0.5mg/kg
Trial: NCT05263986
Drug: MRTX849
RxNorm normalized name: KRAS G12C inhibitor MRTX849
DrugBank: Adagrasib (DB15568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1.
Trial: NCT04659174
Drug: Xanomeline and Trospium Chloride Capsules
RxNorm normalized name: trospium chloride / xanomeline Pill
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
Trial: NCT04566393
Drug: Ulixertinib (BVD-523)
RxNorm normalized name: BVdU
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
Trial: NCT06341296
Drug: Irinotecan Liposome
RxNorm normalized name: Irinotecan liposome
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.
Trial: NCT06341296
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
Trial: NCT06341296
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg/kg, d1, 14 days per cycle, 8 cycles.
Trial: NCT05076409
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1 and period 2
Trial: NCT05076409
Drug: fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 2
Trial: NCT06661967
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of the success rate of endotracheal intubations between lidocaine spray and placebo
Trial: NCT05727800
Drug: VX-668
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for oral administration.
Trial: NCT04691141
Drug: ATG-016
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
Trial: NCT04975919
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06162663
Drug: Suvorexant Tablets
RxNorm normalized name: Suvorexant Tablets
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvorexant initially with 10-20 mg for 28 days
Trial: NCT05177718
Drug: Natalizumab 300 MG in 15 ML Injection
RxNorm normalized name: natalizumab 300 MG in 15 ML Injection
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Disease modifying agent
Trial: NCT05099055
Drug: Dexmedetomidine 0.004 MG/ML [Precedex]
RxNorm normalized name: dexmedetomidine 0.004 MG/ML [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
Trial: NCT04861467
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00002114
Drug: Procysteine
RxNorm normalized name: Procysteine
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06179628
Drug: Low bolus concentration and volume
RxNorm normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare Low and Standard concentrations and volumes of bupivacaine boluses for continuous adductor block
Trial: NCT05858632
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab treatment for \~ 9 months
Trial: NCT05213104
Drug: Flecainide
RxNorm normalized name: Flecainide
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide 150 mg 6 months in addition to standard of care
Trial: NCT05213104
Drug: Flecainide
RxNorm normalized name: Flecainide
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide 150 mg 3 months in addition to standard of care
Trial: NCT05260073
Drug: Tirbanibulin
RxNorm normalized name: TIRBANIBULIN
DrugBank: Tirbanibulin (DB06137)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.
Trial: NCT06252870
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
Trial: NCT06252870
Drug: Anti-Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
Trial: NCT06252870
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
Trial: NCT06252870
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)
Trial: NCT06252870
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)
Trial: NCT06252870
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
Trial: NCT05386550
Drug: Xevinapant (Debio 1143)
RxNorm normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 3 cycles of oral solution of Xevinapant (Debio 1143) at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of Xevinapant (Debio 1143) at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
Trial: NCT05695261
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.
Trial: NCT05638334
Drug: 89Zr-S095012 tracer and S095012 will be administered via an IV infusion
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C.
Trial: NCT06329063
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of vasopressin (20 IU) (oral spray)
Trial: NCT05587231
Drug: Topical Fluorometholone
RxNorm normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid drops will be administered by the subject according to the standard of care taper
Trial: NCT06327399
Drug: Dexmedetomidine infusion
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive Dexmedetomidine infusion dose of 1 mcg/kg over 10 min before induction.
Trial: NCT06327399
Drug: Dexmedetomidine bolus
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive Dexmedetomidine bolus dose of 0.3 mcg/kg over 60 seconds.
Trial: NCT04137588
Drug: Immune checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immune checkpoint inhibitor plus chemotherapy as first line treatment
Trial: NCT04987996
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
Trial: NCT05610826
Drug: Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)
RxNorm normalized name: Lutathera
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRRT is a form of targeted treatment (think of a lock and key) done by the use of a small molecule (Lutathera). Lutathera acts as a key to lock onto certain areas your tumor cells called receptors when injected into a vein and travels through blood.
Trial: NCT06327399
Drug: Atropine Sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If heart rate falls below 45 bpm, rescue dose (500 mcg) of atropine will be given.
Trial: NCT06327399
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If mean blood pressure decreases below 50 mmHg, boluses of 10 mg ephedrine will be given
Trial: NCT06327399
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 20 mg boluses till loss of contact
Trial: NCT04909775
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg per cycle, IV on day 1 of 3-week
Trial: NCT04909775
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
Trial: NCT04909775
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
Trial: NCT05594121
Drug: Extended Release Subcutaneous Buprenorphine
RxNorm normalized name: Buprenorphine Extended-Release Injection
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly subcutaneous injections of long-acting buprenorphine
Trial: NCT05594121
Drug: Immediate Release Sublingual Buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily sublingual fast-acting buprenorphine
Trial: NCT00754949
Drug: 0.1% Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Trial: NCT04640493
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.
Trial: NCT04173260
Drug: Deutetrabenazine 6 MG
RxNorm normalized name: deutetrabenazine 6 MG
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing doses of Deutetrabenazine
Trial: NCT05014464
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
Trial: NCT06090539
Drug: BMS-986458
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days.
Trial: NCT06090539
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days.
Trial: NCT04644237
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
Trial: NCT04776187
Drug: Gadodiamide
RxNorm normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadodiamide Injection(OMNISCAN™)
Trial: NCT04776187
Drug: Gadoteric Acid Meglumine Salt
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
Trial: NCT06375473
Drug: Irinotecan liposome II combination therapy regimen
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan liposome II combination therapy regimen
Trial: NCT06497062
Drug: sonrotoclax
RxNorm normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase.
Trial: NCT06497062
Drug: idarubicin/daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years
Trial: NCT06497062
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).
Trial: NCT06497062
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75 mg/m\^2, subcutaneously, once daily, on D1-7
Trial: NCT06519656
Drug: Mazdutide
RxNorm normalized name: Mazdutide
DrugBank: Mazdutide (DB19099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.
Trial: NCT06662006
Drug: nal-IRI,5-fu,LV, benmelstobart, anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
Trial: NCT06607666
Drug: Lanreotide autogel
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
Trial: NCT05827549
Drug: Blincyto
RxNorm normalized name: Blincyto
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.
Trial: NCT04739618
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
Trial: NCT06252961
Drug: Levamisole 3 days
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
Trial: NCT06252961
Drug: Levamisole 5 days
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole for 5 days (2,5 mg/kg)
Trial: NCT02887040
Drug: Atengenal
RxNorm normalized name: ATENGENAL
DrugBank: Antineoplaston A10 (DB11702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation